EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	4405	514/248 544/236 514/300 546/123	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/27 15:07
L2	475	l1 and quinolone	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/27 15:11
L3	68	l2 and platelet	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/27 15:12
L4	0	l3 and sakae and pyridonecarboxylic	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/27 15:09
L5	327	l1 and $dihydroquinolin$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/27 15:11
L6	59	l5 and platelet	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/12/27 15:12

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:24:39 ON 27 DEC 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:24:54 ON 27 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2007 HIGHEST RN 959588-76-2
DICTIONARY FILE UPDATES: 26 DEC 2007 HIGHEST RN 959588-76-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10-562128genA.str



chain nodes :
11 12 13 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-16 7-20 8-11 11-12 11-18 12-13 13-14 14-15 14-19 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
2-16 5-7 6-10 7-8 7-20 8-9 9-10 11-12 11-18 12-13 13-14 14-15 14-19 16-17
exact bonds :

8-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 15:25:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4281 TO ITERATE

100.0% PROCESSED 4281 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

L2 8 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.76

FILE 'CAPLUS' ENTERED AT 15:26:06 ON 27 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 26 Dec 2007 (20071226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3   8 L2

=> d l2 1-8 abs ibib hitstr
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d l3 1-8 abs ibib hitstr

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

AB Quadruplex nucleotide sequences and methods for identifying interacting mols. are provided. The quadruplex sequences comprise C-rich or G-rich sequences from human genomic DNA and may conform to the motif ((G3+)N1-7)3G3+ or ((C3+)N1-7)3C3+, where "3+" is three or more nucleotides, C is cytosine, G is guanine, and N is any nucleotide. The method for identifying quinoline or porphyrin derivs. that bind to human nucleic acid containing a quadruplex structure or displace a protein from a nucleic acid comprises: (1) contact the nucleic acid and a compound that binds to the nucleic acid with a test mol.; and (2) detecting the amount of the compound bound or not bound to the nucleic acid. The test mol. is identified as a mol. that binds to the nucleic acid containing the human nucleotide sequence when less of the compound binds to the nucleic acid in the presence of the test mol. than in the absence of the test mol. The invention also identifies 1450 quinolone derivs. that bind to quadruplex DNA or RNA sequences. Identifying modulators of nucleic acid synthesis is achieved in a system containing template nucleic acid, primer oligonucleotides, and DNA polymerase or RNA polymerase.

ACCESSION NUMBER: 2007:538440 CAPLUS
DOCUMENT NUMBER: 147:3133
TITLE: Targeting quadruplex sequences in human nucleic acids by identifying interacting quinoline and porphyrin derivatives
INVENTOR(S): O'Brien, Sean; Siddiqui-Jain, Adam
PATENT ASSIGNEE(S): Cylene Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 219pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056113	A2	20070518	WO 2006-US42906	20061102

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-732531P P 20051102
US 2005-735686P P 20051110

IT 936826-07-2
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(targeting quadruplex sequences in human nucleic acids by identifying interacting quinoline and porphyrin derivs.)
RN 936826-07-2 CAPLUS

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[2-(1-pyrrolidinyl)ethyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Process for producing compds. I [X = CR7, N; Y = CR6, N; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3 = halo, alkyl, O-alkyl; R4 = (un)substituted cycloalkyl, non aromatic heterocycle, alkyl substituted by cycloalkyl; further detail on R4 is given.; R5 = H, halo, cyano, etc.; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.; R11 = H, (un)substituted alkyl, optionally substituted amino by (un)substituted alkyl; R12 = H, (un)substituted alkyl, aryl; R11 and R12 may combine to form cyclic amino group in cooperation with the adjacent nitrogen.] or their pharmaceutically acceptable salts, characterized by reaction of compds. II [X, Y, R2-R5 = same as above] or active derivs. thereof with NHR11R12 [R11, R12 = same as above], was provided. For example, to a solution of compound III [R = OH; R' = cyclopentyl] (400 mg) in DMF (5.0 mL) was added 1,1'-carbonyldiimidazole (350 mg) at room temperature, the the reaction was stirred at 100 °C for 20 h. The resulting mixture was treated with Et3N (0.2 mL) and glycine Et ester hydrochloride (180 mg) at room temperature for 5 h to give compound III [R = NHCH2CO2Et; R' = cyclopentyl]. In platelet aggregation inhibition assays, compound III [R = NHCH2CH2P(:O)(OH)2; R' = 2,2-dimethyl-1,3-dioxan-5-yl] exhibited the activity of 92%.

ACCESSION NUMBER: 2006:882644 CAPLUS
DOCUMENT NUMBER: 145:292885
TITLE: Quinolone and related compounds as platelet aggregation inhibitors, and process for the preparation thereof
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Kazunari; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takahashi, Atsushi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006225379	A	20060831	JP 2006-9367	20060118
PRIORITY APPLN. INFO.:			JP 2005-12618 A	20050120

OTHER SOURCE(S): MARPAT 145:292885
IT 836613-50-4P 836617-05-1P 836617-06-2P 836617-18-6P 836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolone and related compds. as platelet aggregation inhibitors)
RN 836613-50-4 CAPLUS

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Glycine, N-[(7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolone and related compds. as platelet aggregation inhibitors)
RN 836621-98-8 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [X = CR7, N; Y = CR6, N; R11 = H, (un)substituted alkyl, optionally substituted amino by (un)substituted alkyl; R12 = H, (un)substituted alkyl, aryl; R11 and R12 may combine to form a (un)substituted cyclic amino group in cooperation with the adjacent nitrogen; R2 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R3 = halo, alkyl, -O-alkyl; R4 = (un)substituted cycloalkyl, non aromatic heterocycle, alkyl substituted by cycloalkyl; further detail on R4 is given.; R5 = H, halo, cyano, etc.; R6 = H, halo, alkyl, etc.; R7 = H, halo, alkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, Pd/C catalyzed debenzylation of compound II [R = OCH2Ph] under H2 afforded compound II [R = OH]. In platelet aggregation inhibition assays, compound II [R = OH] exhibited the activity of 92%.

ACCESSION NUMBER: 2006:882641 CAPLUS
DOCUMENT NUMBER: 145:292884
TITLE: Preparation of quinolone derivatives as platelet aggregation inhibitors
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Kazunari; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Atsushi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 95pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006225378	A	20060831	JP 2006-9349	20060118
PRIORITY APPLN. INFO.:			JP 2005-12561 A	20050120

OTHER SOURCE(S): MARPAT 145:292884
IT 836613-50-4P 836617-05-1P 836617-06-2P
836617-18-6P 836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolone derivs. as platelet aggregation inhibitors)
RN 836613-50-4 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolone derivs. as platelet aggregation inhibitors)
RN 836621-98-8 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB The title compds. (I) and pharmaceutically acceptable salts thereof characterized by each having an amide group at the 3-position which is substituted with a substituent having a carboxylate ester, phosphate ester, sulfate ester or the like, and an amino group at the 7-position which is substituted with a substituent having a ring structure [Y = C-R6; R6 = H, halo, lower alkyl, halo-lower alkyl; R2 = each (un)substituted lower alkyl, cycloalkyl, aryl, or heterocyclyl; R3 = halo; R5 = H, HO, halo; R11 = H, lower alkyl or lower alkyl-amino wherein lower alkyl is optionally substituted; R12 = (un)substituted lower alkyl] are prepared These compds. have excellent P2Y12 (adenine diphosphate receptor) inhibitory effect and platelet agglutination inhibitory effect and consequently are useful as platelet agglutination inhibitors. Thus, hydrogenolysis of [2-(([7-(Cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino)ethyl]phosphonic acid dibenzyl ester over 10% Pd-C in MeOH under hydrogen atmospheric for 3 h gave [2-(([7-(Cyclohexylamino)-1-(2,2-dimethyl-1,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl)amino)ethyl]phosphonic acid (II). II inhibited ADP-induced aggregation of human blood platelet by 92% at 10 μM and the binding of [3H]-2-MeS-ADP to human P2Y12 by 96% at 30 nM.

ACCESSION NUMBER: 2006:733081 CAPLUS
DOCUMENT NUMBER: 145:188746
TITLE: Preparation of 4-quinolone-3-carboxamide derivatives and salts thereof as platelet aggregation inhibitors
INVENTOR(S): Koga, Yuji; Okuda, Takao; Hirabayashi, Ryoji; Fujiyasu, Jiro; Miyazaki, Takehiro; Watanuki, Susumu; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Jun
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 150 pp.

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077851	A1	20060727	WO 2006-JP300590	20060118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-12715 A 20050120

OTHER SOURCE(S): MARPAT 145:188746

IT 836621-98-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 4-oxoquinoline-3-carboxamide derivs. and salts thereof as platelet aggregation inhibitors and P2Y12 receptor inhibitors)

RN 836621-98-8 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 836613-50-4P, [[[7-[(Cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl]amino]acetic acid
836617-05-1P 836617-06-2P 836617-18-6P
836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-oxoquinoline-3-carboxamide derivs. and salts thereof as platelet aggregation inhibitors and P2Y12 receptor inhibitors)

RN 836613-50-4 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 836617-05-1 CAPLUS
CN Glycine, N-[[7-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted (hetero)aryl which may be monocyclic or fused with a single or multiple ring and optionally containing a heteroatom; R5 = H, OR2, alkyl, alkenyl, etc.] or II [V, A, X, Z, and U are as defined above; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful in screening and for inducing apoptosis. Over forty synthetic examples showed the synthesis of intermediates and target compds. E.g., a multi-step synthesis of the amide III, starting from 2,3,4,5-tetrafluorobenzoic acid, was given. The title compds. were tested in various tests. For example, they were tested in a stop assay, a high throughput, first-pass screen detecting drugs that bind to and stabilize the target G-quadruplex. E.g., the compound III exhibits approx. 400x selectivity for the c-Myc quadruplex relative to pUC 18 plasmid DNA. III was also tested for antitumor activity (biol. data given). The pharmaceutical composition comprising the compds. I or II is disclosed.

ACCESSION NUMBER: 2006:120542 CAPLUS
DOCUMENT NUMBER: 144:212787
TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 558 pp., Cont.-in-part of U.S. Ser. No. 903,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006029950	A1	20060209	US 2005-106909	20050415
US 7141565	B1	20061128	US 2004-821243	20040407
US 2005085468	A1	20050421	US 2004-903975	20040730
AU 2005325210	A1	20060727	AU 2005-325210	20050729
CA 2575547	A1	20060727	CA 2005-2575547	20050729
WO 2006078317	A1	20060727	WO 2005-US26977	20050729

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1773346 A1 20070418 EP 2005-856890 20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRIORITY APPLN. INFO.: US 2003-461271P P 20030407
US 2003-463171P P 20030415
US 2003-519535P P 20031112
US 2003-532727P P 20031223
US 2004-821243 A2 20040407
US 2004-903975 A2 20040730
US 2005-106909 A 20050415
WO 2005-US26977 W 20050729

OTHER SOURCE(S): MARPAT 144:212787

IT 783361-99-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-99-9 CAPLUS
CN L-Serine, N-([5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μM. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

ACCESSION NUMBER: 2005:349002 CAPLUS
DOCUMENT NUMBER: 142:373851
TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 453 pp., Cont.-in-part of U.S. Ser. No. 821,243.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005085468	A1	20050421	US 2004-903975	20040730
US 7141565	B1	20061128	US 2004-821243	20040407
US 2006029950	A1	20060209	US 2005-106909	20050415
AU 2005325210	A1	20060727	AU 2005-325210	20050729
CA 2575547	A1	20060727	CA 2005-2575547	20050729
WO 2006078317	A1	20060727	WO 2005-US26977	20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,				

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

	SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1773346	A1	20070418	EP 2005-856890	20050729
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 2006229303	A1	20061012	US 2006-390810	20060328
US 2007043039	A1	20070222	US 2006-431602	20060510
PRIORITY APPLN. INFO.:			US 2003-461271P	P 20030407
			US 2003-463171P	P 20030415
			US 2003-519535P	P 20031112
			US 2003-532727P	P 20031223
			US 2004-821243	A2 20040407
			US 2004-903975	A2 20040730
			US 2005-106909	A 20050415
			WO 2005-US26977	W 20050729

OTHER SOURCE(S): MARPAT 142:373851
IT 783361-99-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted quinobenzoxazine analogs as antitumor agents)
RN 783361-99-9 CAPLUS
CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I



II

AB Title compds. I [X = CR7, N; Y = CR6, N; R11 = H, (un)substituted alkyl, etc.; R12 = H, (un)substituted alkyl, etc.; R2 = (un)substituted alkyl, etc.; R3 = halo, etc.; R4 = (un)substituted cycloalkyl, etc.; R5 = H, halo, etc.; R6 = H, halo, etc.; R7 = H, halo, etc.] were prepared For example, hydrogenolysis of compound II [A = OCH2Ph] afforded compound II [A = OH]. In platelet aggregation inhibition assays, compound II [A = OH] exhibited inhibition activity of 92%. Compds. I are claimed useful as platelet aggregation inhibitors, P2Y12 inhibitors.

ACCESSION NUMBER: 2005:99478 CAPLUS
DOCUMENT NUMBER: 142:197896
TITLE: Preparation of quinolone derivatives as platelet aggregation inhibitors
INVENTOR(S): Watanuki, Susumu; Koga, Yuji; Moritomo, Hiroyuki; Tsukamoto, Issei; Kaga, Daisuke; Okuda, Takao; Hirayama, Fukushi; Moritani, Yumiko; Takasaki, Jun
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

WO 2005009971 A1 20050203 WO 2004-JP10781 20040722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
JP 2005053903 A 20050303 JP 2004-212326 20040720
CA 2530352 A1 20050203 CA 2004-2530352 20040722
EP 1650192 A1 20060426 EP 2004-748045 20040722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
CN 1826321 A 20060830 CN 2004-80021187 20040722
US 2006148806 A1 20060706 US 2005-562128 20051223
IN 2006DN00144 A 20070824 IN 2006-DN144 20060109
MX 2006PA00675 A 20060419 MX 2006-PA675 20060118
PRIORITY APPLN. INFO.: JP 2003-278852 A 20030724
WO 2004-JP10781 W 20040722

OTHER SOURCE(S): MARPAT 142:197896

IT 836613-50-4P 836617-05-1P 836617-06-2P
836617-18-6P 836617-19-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolone derivs. as platelet aggregation inhibitors, P2Y12 inhibitors)

RN 836613-50-4 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



RN 836617-05-1 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 836617-06-2 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 836617-18-6 CAPLUS
CN Glycine, N-[[1-ethyl-6-fluoro-1,4-dihydro-7-[(1-methylethyl)amino]-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



RN 836617-19-7 CAPLUS
CN Glycine, N-[[7-[(1,1-dimethylethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]- (CA INDEX NAME)



L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 836621-98-8P, tert-Butyl [([7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl]amino]acetate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolone derivs. as platelet aggregation inhibitors, P2Y12 inhibitors)

RN 836621-98-8 CAPLUS
CN Glycine, N-[[7-[(cyclohexylmethyl)amino]-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μM. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

ACCESSION NUMBER: 2004:902098 CAPLUS
DOCUMENT NUMBER: 141:395565
TITLE: Preparation of substituted quinobenzoxazine analogs as antitumor agents
INVENTOR(S): Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terrance
PATENT ASSIGNEE(S): Cyclene Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091504	A2	20041028	WO 2004-US11108	20040407
WO 2004091504	A3	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,

TD, TG

AU 2004229489	A1	20041028	AU 2004-229489	20040407
CA 2521810	A1	20041028	CA 2004-2521810	20040407
EP 1610759	A2	20060104	EP 2004-759406	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009105	A	20060425	BR 2004-9105	20040407
CN 1809572	A	20060726	CN 2004-80014351	20040407
JP 2006522827	T	20061005	JP 2006-509898	20040407
MX 2005PA10776	A	20060525	MX 2005-PA10776	20051006
NO 2005004669	A	20051114	NO 2005-4669	20051011
IN 2005KN02147	A	20070727	IN 2005-KN2147	20051031

PRIORITY APPLN. INFO.:

US 2003-461271P	P	20030407
US 2003-463171P	P	20030415
US 2003-519535P	P	20031112
US 2003-532727P	P	20031223
WO 2004-US11108	W	20040407

OTHER SOURCE(S): MARPAT 141:395565

IT 783361-99-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-99-9 CAPLUS

CN L-Serine, N-[[5-fluoro-9,14-dihydro-3,9,14-trioxo-6-[[3-(1-pyrrolidinyl)propyl]amino]-3H-naphtho[2,3-b]pyrido[3,2,1-kl]phenoxazin-2-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

```
=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 15:30:55 ON 27 DEC 2007
```